Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma

Clinical Cancer Research

Volumn 13, Issue 11, 2007, Pages 3380-3387

  Drakos, Elias ^a   Thomaides, Athanasios ^a   Medeiros, L Jeffrey ^a   Li, Jiang ^a   Leventaki, Vasiliki ^a   Konopleva, Marina ^a   Andreeff, Michael ^a   Rassidakis, George Z ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLIN DEPENDENT KINASE INHIBITOR; LEPTOMYCIN B; NUTLIN 3A; P21 ACTIVATED KINASE; PROTEASOME; PROTEIN BAX; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HODGKIN DISEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN STABILITY; REED STERNBERG CELL; UPREGULATION;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; GENES, P53; HODGKIN DISEASE; HUMANS; IMIDAZOLES; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34250669968     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2581     Document Type: Article

References (43)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
3. Schuler M, Green DR. Transcription, apoptosis, and p53: catch-22. Trends Genet 2005;21:182-7.
4. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006;21:307-15.
5. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24: 2899-908.
6. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80-3.
7. Zhang R, Wang H, Agrawal S. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr Cancer Drug Targets 2005;5:43-9.
8. Poyurovsky MV, Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev 2006; 20:125-31.
9. Vassilev LT. p53 Activation by small molecules: application in oncology. J Med Chem 2005;48:4491-9.
10. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
11. Tovar C, Rosinski J, Filipovic Z , et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888-93.
12. Stuhmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106:3609-17.
13. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106:3150-9.
14. Secchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107:4122-9.
15. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006;107:4109-14.
16. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Mdm2 and Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006;108:993-1000.
17. Stein H. Hodgkin lymphomas. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2001. p. 239.
18. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84.
19. Behringer K, Josting A, Schiller P, et al. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004;15:1079-85.
20. Chronowski GM, Wilder RB, Levy LB, et al. Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol 2004;27:73-80.
21. Bhatia S, Meadows AT, Robison LL. Second cancers after pediatric Hodgkin's disease. J Clin Oncol 1998;16:2570-2.
22. Linch DC, Gosden RG, Tulandi T, Tan SL, Hancock SL. Hodgkin's lymphoma: choice of therapy and late complications. Hematology Am Soc Hematol Educ Program 2000;205-21.
23. Montesinos-Rongen M, Roers A, Kuppers R, Rajewsky K, Hansmann ML. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood 1999;94:1755-60.
24. Trumper LH, Brady G, Bagg A, et al. Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood 1993;81:3097-115.
25. Xerri L, Parc P, Bouabdallah R, Camerlo J, Hassoun J. PCR-mismatch analysis of p53 gene mutation in Hodgkin's disease. J Pathol 1995;175:189-94.
26. Elenitoba-Johnson KS, Medeiros LJ, Khorsand J, King TC. P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's disease. Am J Clin Pathol 1996;106:728-38.
27. Sanchez-Beato M, Piris MA, Martinez-Montero JC, et al. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. J Pathol 1996; 180:58-64.
28. Kupper M, Joos S, von Bonin F, et al. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol 2001;112:768-75.
29. Maggio EM, Stekelenburg E, Van den Berg A, Poppema S. TP53 genemutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus. Int J Cancer 2001;94:60-6.
30. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma 1993;9:1-25.
31. Hubinger G, Muller E, Scheffrahn I, et al. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene 2001; 20:590-8.
32. Rassidakis GZ, Thomaides A, Wang S, et al. p53 gene mutations are uncommon but p53 is commonly expressed in anaplasticl arge-cell lymphoma. Leukemia 2005;19:1663-9.
33. Guenova M, Rassidakis GZ, Gorgoulis VG, et al. p16INK4A is regularly expressed in Hodgkin's disease: comparison with retinoblastoma, p53 and MDM2 protein status, and the presence of Epstein-Barr virus. Mod Pathol 1999;12:1062-71.
34. Glossmann JP, Josting A, Diehl V. New treatments for Hodgkin's disease. CurrTreat Options Oncol 2002; 3:283-90.
35. Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol 2005;23: 6379-86.
36. Chen WG, Chen YY, Kamel OW, Koo CH, Weiss LM. p53 mutations in Hodgkin's disease. Lab Invest 1996; 75:519-27.
37. Garcia JF, Villuendas R, Sanchez-Beato M, et al. Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/ Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts. Am J Pathol 2002;160:569-78.
38. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
39. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95.
40. Thompson T, Tovar C, Yang H, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004;279: 53015-22.
41. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005;65:1918-24.
42. Teodoro JG, Parker AE, Zhu X, Green MR. p53-mediated inhibition of angiogenesis through upregulation of a collagen prolyl hydroxylase. Science 2006;313:968-71.
43. Kiaris H, Chatzistamou I, Trimis G, Frangou-Plemmenou M, Pafiti-Kondi A, Kalofoutis A. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 2005;65:1627-30.